Longterm Followup of Rituximab Therapy in Patients with Rheumatoid Arthritis: Results from the Belgian MabThera in Rheumatoid Arthritis Registry

Keyser, Filip De; Hoffman, Ilse; Durez, Patrick; Kaiser, Marie‐Joëlle; Westhovens, René

doi:10.3899/jrheum.131279

Cited by 32 publications

(28 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For several biologic DMARDs, evidence exists that response differs by serologic status. Rituximab 56 and abatacept 78 have been shown to have better efficacy in those with anti-CCP antibodies in multiple studies. There is no evidence, however, for superior efficacy of any biologic DMARD in patients with seronegative RA.…”

Section: Introductionmentioning

confidence: 99%

Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis

Cappelli

Palmer²,

Kremer

et al. 2017

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

Objective Autoantibodies can be useful in predicting response to certain treatments in rheumatoid arthritis (RA). We aimed to evaluate initial response to tocilizumab (TCZ) by change in physician and patient reported outcomes and laboratory parameters in a real world cohort of patients with RA. We analyzed data by autoantibody status to determine whether patients with seronegative RA had improved response to tocilizumab when compared to their seropositive counterparts. Methods Data from the CORRONA RA registry was analyzed. Patients were included if they were started on TCZ and had data from a follow up visit 4-8 months after initiation, as well as having information on serologic status. Serologic status was determined by presence of anti-cyclic citrullinated peptide (CCP) antibodies. Changes in disease activity measures from baseline to follow up visit were evaluated. Results Both CCP negative and positive groups had statistically significant improvement in physician reported measurements (physician rating of disease activity, joint counts), patient reported measures (disease activity, pain, fatigue), and acute phase reactants after 4-8 months of treatment with tocilizumab. The magnitude of improvement, however, did not differ significantly by CCP status. Conclusion Tocilizumab led to statistically significant improvement in all patient and physician reported measures of disease activity evaluated in this cohort of patient with RA. The response to tocilizumab did not differ by CCP status.

show abstract

Section: Introductionmentioning

confidence: 99%

Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis

Cappelli

Palmer²,

Kremer

et al. 2017

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

show abstract

“…1). Because of some differences in the population studied, baseline demographics, and disease characteristics, the results of pivotal, large trials [1][2][3][4][5][6] and long-term studies ranging from 2 to 5 years using the innovator biologic [6][7][8] cannot be directly compared with our cohort. However, overall, our results underscore the benefits of (biosimilar) rituximab usage in biologic naive patients with RA and an inadequate response to methotrexate.…”

Section: Discussionmentioning

confidence: 97%

“…Rituximab, an anti-CD20 monoclonal antibody, has proven efficacy and safety in the treatment of rheumatoid arthritis (RA) including in the biological naïve patients [1][2][3][4][5][6][7][8]. Cost has been identified as a key limitation of the current biologic usage including of rituximab globally, and therefore, impetus is there to develop and license follow-on or Bbiosimilar^versions of these Breference (originator or innnovator)^biological products [9,10].…”

mentioning

confidence: 99%

Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis

Roshique

Ravindran

2015

Clin Rheumatol

View full text Add to dashboard Cite

Biosimilar usage in rheumatology is set to increase over the next few years. This study reports the efficacy and toxicity of a rituximab biosimilar in biologic naïve patients with active rheumatoid arthritis who had inadequately responded to methotrexate. In 21 patients, over a follow-up period of 36 months, it demonstrated prolonged benefit in a majority (10 in remission with disease activity score 28 (DAS28) erythrocyte sedimentation rate (ESR) <2.6 and 9 in low disease activity state with DAS28 ESR between 3.2 and 2.6) and was well tolerated.

show abstract

“…Регистр MIRA В регистр MIRA (MabThera In Rheumatoid Arthritis) [18] были включены пациенты, получающие РТМ, с непе-реносимостью и/или неэффективностью хотя бы одного иФНОα в анамнезе. К 16-й неделе терапии у 78,2% паци-ентов, получающих РТМ, отмечался умеренный ответ по критериям EULAR, значение индекса DAS28 со временем уменьшалось (ANOVA; p<0,001), при этом динамика DAS28 была максимальной в первый год лечения РТМ, с последующей стабилизацией.…”

Section: исследование Variarunclassified

The Efficacy and Safety of Rituximab in Rheumatoid Arthritis: New Evidence

Kusevich¹,

Авдеева²

2017

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune rheumatic disease characterized by chronic erosive arthritis (synovitis) and a systemic inflammatory lesion of the internal organs, which results in early disability and worse quality of life in patients. The accumulated data on the efficacy, safety, and cost-effectiveness of anti-B cell therapy allow identification of rituximab (RTM) as an extremely important drug of first- or second-line therapy with biological agents after ineffective treatment with tumor necrosis factor-α (TNF-α) inhibitors. In this connection, the choice of a personalized treatment regimen remains relevant in each specific case as before. Clinical experience with RTM suggests that the drug is highly effective in improving both clinical manifestations and quality of life in patients with active RA that is characterized by resistance to disease-modifying antirheumatic drugs and TNF-α inhibitors, as well as in those with early RA. The current literature presents a large amount of data on the role of prior therapy and the impact of the stage of RA when using different RTM doses on its efficiency, some of which will be discussed in this review.

show abstract

Longterm Followup of Rituximab Therapy in Patients with Rheumatoid Arthritis: Results from the Belgian MabThera in Rheumatoid Arthritis Registry

Abstract: In our daily practice study, RTX provided good longterm disease control and treatment retention in refractory patients with RA. Over the years, rheumatologists tended to start this treatment in patients with fewer previous anti-TNF treatments and lower disease activity.

Cited by 32 publications

References 16 publications

Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis

Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis

Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis

The Efficacy and Safety of Rituximab in Rheumatoid Arthritis: New Evidence

Contact Info

Product

Resources

About